Johnson & Johnson will present data from more than 20 clinical and real-world studies at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The research highlights advancements in solid tumors and hematologic malignancies.
The ASCO plenary session will feature late-breaking Phase 3 data for ERLEADA in high-risk prostate cancer. This study signals a potential shift in treatment standards for the disease.
The company will also release positive Phase 3 results for TECVAYLI in multiple myeloma. Additionally, J&J will present pivotal data for RYBREVANT FASPRO in advanced head and neck cancer.